Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane

Table 2

Difference in the central retinal thickness (CRT) change between subgroups.

	Number of eyes	Mean CRT at baseline μm (range)	Mean CRT at 12 months μm (range)	Mean reduction CRT, μm (range)	value 0–12 m	Patients with worsening or no reduction CRT (%)
Total	58	627 (244, 991)	359 (186, 983)	267 (−411, +741)	<0.001	9 (16%)
PRN	42	631 ± 193 (244, 991)	371 ± 182 (186, 983)	258 ± 258 (−411, 741)	<0.001	7 (17%)
TER	16	615 ± 141 (428, 971)	327 ± 84 (237, 537)	288 ± 196 (−59, 734)	<0.001	2 (13%)
value baseline		0.74
ERM	16	639 ± 210 (244, 991)	385 ± 125 (223 to 674)	255 ± 274 (−270, 741)	0.003	5 (31%)
Non-ERM	42	622 ± 167 (300, 980)	350 ± 173 (186 to 983)	271 ± 230 (−411, 734)	<0.001	4 (10%)
value baseline		0.7

value, measure the significance of the difference in the CRT change between subgroups at baseline. value 0–12 m = the significance of the difference between baseline and 12 months in the same subgroup. PRN, pro re nata regime; TER, treat-and-extend regimen. ERM, epiretinal membrane; non-ERM, eyes which did not develop an ERM during the first 6 months of treatment.